Stefano Del Prato

1982–2025 年に発表

208
論文数
46,737
被引用数
100
h 指数
202
i10 指数

被引用数

Stefano Del Prato の年別被引用数1983 年: 被引用 2 件1984 年: 被引用 1 件1985 年: 被引用 4 件1986 年: 被引用 3 件1987 年: 被引用 5 件1988 年: 被引用 3 件1989 年: 被引用 8 件1990 年: 被引用 6 件1991 年: 被引用 7 件1992 年: 被引用 11 件1993 年: 被引用 5 件1994 年: 被引用 9 件1995 年: 被引用 21 件1996 年: 被引用 19 件1997 年: 被引用 30 件1998 年: 被引用 31 件1999 年: 被引用 31 件2000 年: 被引用 52 件2001 年: 被引用 45 件2002 年: 被引用 57 件2003 年: 被引用 76 件2004 年: 被引用 120 件2005 年: 被引用 132 件2006 年: 被引用 144 件2007 年: 被引用 164 件2008 年: 被引用 214 件2009 年: 被引用 173 件2010 年: 被引用 197 件2011 年: 被引用 225 件2012 年: 被引用 276 件2013 年: 被引用 330 件2014 年: 被引用 340 件2015 年: 被引用 349 件2016 年: 被引用 349 件2017 年: 被引用 343 件2018 年: 被引用 381 件2019 年: 被引用 1,365 件2020 年: 被引用 1,612 件2021 年: 被引用 1,576 件2022 年: 被引用 1,236 件2023 年: 被引用 1,086 件2024 年: 被引用 2,076 件2025 年: 被引用 1,125 件2026 年: 被引用 42 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,971 件、この内訳の 17.4%イギリス: 引用元論文 1,903 件、この内訳の 8.3%イタリア: 引用元論文 1,622 件、この内訳の 7.1%中国: 引用元論文 1,476 件、この内訳の 6.5%ドイツ: 引用元論文 1,030 件、この内訳の 4.5%カナダ: 引用元論文 817 件、この内訳の 3.6%オーストラリア: 引用元論文 756 件、この内訳の 3.3%スペイン: 引用元論文 738 件、この内訳の 3.2%スウェーデン: 引用元論文 712 件、この内訳の 3.1%デンマーク: 引用元論文 626 件、この内訳の 2.8%オランダ: 引用元論文 621 件、この内訳の 2.7%フランス: 引用元論文 619 件、この内訳の 2.7%
0%17.4%その他 34.8%

分野

  • Medicine79.7%
  • Biochemistry, Genetics and Molecular Biology12.3%
  • Nursing1.2%
  • Health Professions1.1%
  • Immunology and Microbiology1.1%
  • Neuroscience1%
  • その他3.6%

トピック

  • Diabetes Treatment and Management9.5%
  • Pancreatic function and diabetes5.8%
  • Diabetes Management and Research4.7%
  • Metabolism, Diabetes, and Cancer3.8%
  • Diabetes, Cardiovascular Risks, and Lipoproteins3.4%
  • Diabetes and associated disorders2.8%
  • その他70%

共著者

全論文

検索で開く
  1. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

    著者: , , , , , , , , , , , - The Lancet Diabetes & Endocrinology 2021 被引用: 1,502

  2. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

    著者: , , , , , , , , , , , , , - Diabetes Care 2022 被引用: 1,950

  3. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David C. M. Kong, Gerald S. Bloomfield, Matthew T. Roe, Pierluigi Tricoci, Robert W. Harrison, Renato D. Lópes, Robin Mathews, Rajendra Mehta, W. Schuyler Jones, Sreekanth Vemulapalli, Thomas J. Povsic, Zubin J. Eapen, Keith Dombrowski, Brad J. Kolls, J. Dedrick Jordan, Andrew P. Ambrosy, Stephen J. Greene, Aditya Mandawat, Jay Shavadia, Lauren B. Cooper, Abhinav Sharma, Patrícia O. Guimarães, Daniel J. Friedman, Matthew E. Wilson, Patricia Endsley, Tracy Gentry, Jeannie Collier, Kathleen Perez, K.E. James, Jennifer Roush, C. ARDEN III POPE, Christina Howell, Megan Johnson, M. Bailey, Joanna Cole, Teresa Akers, Beth Vandyne, Betsy Thomas, Jenny Rich, Susan Bartone, Gail Beaulieu, Kim Brown, Tuan Chau, Tamra Christian, Rebecca Coker, Deb Greene, Trevorlyn Haddock, Wendy Jenkins, Ghazala Haque, Marsha L. Marquess, Jean Pesarchick, Renee Rethaford, Allegra Stone, Firas Al- Kawas, Michelle A. Anderson, Robert Enns, Isaac Sinay, Chantal Mathieu, Victor Yordanov, Irene Hramiak, Martin Haluzı́k, Søren Galatius, Bruno Guerci, Michael A. Nauck, Ilias Migdalis, Choon Beng Kathryn Tan, Győző Kocsis, Andrea Giaccari, Moon Kyu Lee, Ernesto Muñoz ほか 708 名 - The Lancet 2018 被引用: 1,791

  4. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

    著者: , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 777

  5. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Julio Rosenstock, Banshi Saboo, Kohjiro Ueki, Guillermo E Umpierrez, Stuart A. Weinzimer, Moshe Phillip - The Lancet Diabetes & Endocrinology 2022 被引用: 725

  6. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Luis Herandez-Vazquez, Stanley H. Hsia, Michael Jardula, E. Klein, Mark E Kutner, Juan Loy, Francisco G Miranda, Lazaro Nunez, Miguel Mujica-Baella, Alexander V. Murray, Michael Oliver, Ramon Oritz-Carrasquillo, Betsy Palal, Michael T Parke, Athena Philis‐Tsimikas, Raman Purighalla, Julio Rosenstock, Airani Sathananthan, Courtney Shelton, Kanagaratnam Sivalingam, Ehab Sorial, Joseph Soufer, Helen L Stacey, Larry D. Stonesifer, Stanley Stringam, Joanna Van, Jose Vazquez-Tanus, Ramón López de los Reyes, Michelle Welch, Najmuddin Karimjee, Earl E Martin, Ahmed A. Arif, Timothy W Jennings, Neil J. Fraser, Anuj Bhargava, Alan Wynne, Evelyne Davidson, Liana K. Billings, Elizabeth A Barranco-Santana, Michael Dever, Patrick Walsh, A.K. Cho, James W. Chu, Jay H. Shubrook, Albert B. Knouse, Venkatesh Nadar, Lorena Lewy-Alterbaum, Michael Lillestol, Daniel J Humiston, Alexander White, Ronald K. Mayfield, Fahed Bitar, Fernando Cereto, Carmen de la Cuesta, L. de Teresa Parreño, Esteban Jódar Gimeno, Pedro Mezquita‐Raya, Cristobal J Morales Portillo, Miguel Quesada Charneco, Francisco J. Tinahones, Santiago Tofe Povedano, Luis Alberto Vázquez, Carmen Fajardo Montañana, Alfonso González, Cristina Mistodie, Iosif Szilagyi, Adriana Filimon, Nicoleta Mîndrescu, Lavinia Pop, Marlena Pascu ほか 109 名 - The Lancet 2021 被引用: 642

  7. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeroen J. Bax, H. Baumgartner, Claudio Ceconi, V. Dean, Christi Deaton, Robert Fagard, Christian Funck‐Brentano, David Hasdai, A. Hoes, Paulus Kirchhof, Juhani Knuuti, Philippe Kolh, Theresa A. McDonagh, Bruno Moulin, Bogdan A. Popescu, Z. Reiner, U Sechtem, P. A. Sirnes, Michał Tendera, Adam Torbicki, A. Vahanian, Stephan Windecker, Document Reviewers:, Christian Funck‐Brentano, P. A. Sirnes, Victor Aboyans, Eduardo Alegría Ezquerra, Colin Baigent, Carlos Brotons, G. Burell, Antonio Ceriello, Johan De Sutter, J. Deckers, Stefano Del Prato, H.‐C. Diener, Donna Fitzsimons, Zlatko Fras, Rainer Hambrecht, Piotr Jankowski, U Keil, Mike Kirby, Mogens Lytken Larsen, Giuseppe Mancia, Athanasios Manolis, John J.V. McMurray, A. Pajak, Alexander Parkhomenko, Loukianos Rallidis, Fausto Rigo, Evangelista Rocha, Luís M. Ruilope, Enno T. van der Velde, Diego Vanuzzo, Margus Viigimaa, Massimo Volpe, Olov Wiklund, C. Wolpert - European Heart Journal 2012 被引用: 8,519

  8. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

    著者: , , , , , , , , , , , , , , , , , , , - American Heart Journal 2023 被引用: 222

  9. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

    著者: , , - The Lancet 2013 被引用: 1,747

  10. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

    著者: , , , , , , - Diabetologia 2022 被引用: 257

  11. Practical Algorithms for Early Diagnosis of Heart Failure and Heart Stress Using NT-proBNP: A Clinical Consensus Statement from the Heart Failure Association of the ESC

    著者: , , , , , , , , , , , , , , , , , , , , - European Journal of Heart Failure 2023 被引用: 227

  12. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

    著者: , , , , , - The Lancet 2019 被引用: 355

  13. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial

    著者: , , , , , , , , , , , - Circulation 2021 被引用: 127

  14. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Desmond G. Johnston, Sangeeta R. Kashyap, Tracy Kelly, Tomasz Klupa, Judith Körner, Blandine Laferrère, Harold E. Lebovitz, Wei‐Jei Lee, Carel W. le Roux, Jeffrey I. Mechanick, Geltrude Mingrone, John M. Morton, Walter J. Pories, Robert E. Ratner, Gerry Rayman, Harvey J. Sugerman, Luc Van Gaal, Josép Vidal, Jianping Weng, Bruce M. Wolfe - Diabetes Care 2016 被引用: 971

  15. GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes

    著者: , , , , , , , , , , , - Journal of the American College of Cardiology 2023 被引用: 60

  16. COVID-19, Hyperglycemia, and New-Onset Diabetes

    著者: , , , , , - Diabetes Care 2021 被引用: 324

  17. New-Onset Diabetes in Covid-19

    著者: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 828

  18. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients

    著者: , , , , , , , , , - Diabetologia 2005 被引用: 386

  19. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Norman E. Lepor, Christos S. Mantzoros, Chantal Mathieu, Christian W. Mende, Erin D. Michos, Javier Morales, Jorge Plutzky, Richard E. Pratley, Kausik K Ray, Peter Rossing, Naveed Sattar, Peter E.H. Schwarz, Eberhard Standl, Philippe Gabríel Steg, Lâle Tokgözoğlu, Jaakko Tuomilehto, Guillermo E Umpierrez, Paul Valensi, Matthew R. Weir, John Wilding, Eugene E. Wright - Metabolism 2024 被引用: 76

  20. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study

    著者: , , , , , , , , , , , - Diabetes Care 2020 被引用: 64

  21. The impact of the COVID-19 pandemic on diabetes services: planning for a global recovery

    著者: , , , , , , , , , , , - The Lancet Diabetes & Endocrinology 2022 被引用: 107

  22. Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics

    著者: , , , , , , , , , , , - American Heart Journal 2018 被引用: 95

  23. Review of methods for detecting glycemic disorders

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Diabetes Research and Clinical Practice 2020 被引用: 194

  24. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion

    著者: , , , , , , , , , - Diabetologia 2008 被引用: 495